

1 Full title: Special Olympics global report on COVID-19 vaccination and reasons not to vaccinate
2 among adults with intellectual disabilities

3

4 Short title: Special Olympics global report on COVID-19 vaccination

5

6 Andrew E. Lincoln^{1,2¶*}, Alicia M. Dixon-Ibarra^{1,3¶}, John P. Hanley^{1¶}, Ashlyn L. Smith^{1&}, Kiki
7 Martin^{1&}, Alicia Bazzano^{1&}

8

9 ¹ Special Olympics, Inc., Washington, DC, United States of America

10 ² Georgetown University Medical Center, Department of Rehabilitation Medicine, Washington,
11 DC, United States of America

12 ³ Oregon State University, College of Public Health and Human Sciences, Corvallis, OR, United
13 States of America

14

15 * Corresponding author: Andrew Lincoln, E-mail: alincoln@specialolympics.org

16 ¶ These authors contributed equally to this work.

17 & These authors also contributed equally to this work

18 **Abstract**

19

20 Introduction: The COVID-19 pandemic has disproportionately affected people with intellectual
21 disabilities worldwide. The objective of this study was to identify global rates of COVID-19
22 vaccination and reasons not to vaccinate among adults with intellectual disabilities (ID)
23 associated with country economic income levels.

24

25 Methods: The Special Olympics COVID-19 online survey was administered in January-February
26 2022 to adults with ID from 138 countries. Descriptive analyses of survey responses include
27 95% margins of error. Logistic regression and Pearson Chi-squared tests were calculated to
28 assess associations with predictive variables for vaccination using R 4.1.2 software.

29

30 Results: Participants (n=3560) represented 18 low (n=410), 35 lower-middle (n=1182), 41 upper-
31 middle (n=837), and 44 high (n=1131) income countries. Globally, 76% (74.8-77.6%) received a
32 COVID-19 vaccination while 49.5% (47.9-51.2%) received a COVID-19 booster. Upper-middle
33 (93% (91.2-94.7%)) and high-income country (94% (92.1-95.0%)) participants had the highest
34 rates of vaccination while low-income countries had the lowest rates (38% (33.3-42.7%)). In
35 multivariate regression models, country economic income level (OR = 3.12, 95% CI [2.81,
36 3.48]), age (OR = 1.04, 95% CI [1.03, 1.05]), and living with family (OR = 0.70, 95% CI [0.53,
37 0.92]) were associated with vaccination. Among LLMICs, the major reason for not vaccinating
38 was lack of access (41.2% (29.5-52.9%)). Globally, concerns about side effects (42%, (36.5-
39 48.1%)) and parent/guardian not wanting the adult with ID to vaccinate (32% (26.1-37.0%))
40 were the most common reasons for not vaccinating.

41

42 Conclusion: Adults with ID from low and low-middle income countries reported fewer COVID-
43 19 vaccinations, suggesting reduced access and availability of resources in these countries.
44 Globally, COVID-19 vaccination levels among adults with ID were higher than the general
45 population. Interventions should address the increased risk of infection for those in congregate
46 living situations and family caregiver apprehension to vaccinate this high-risk population.

47

- 48 Key words (5-8): Special Olympics, COVID-19, vaccination, reasons not to vaccinate, global,
49 intellectual disabilities

50 **Introduction**

51 The COVID-19 pandemic has impacted people with intellectual disabilities (ID) across
52 the world. Intellectual disability originates during early human development and is defined by
53 significant limitations in intellectual functioning and adaptive functioning in conceptual, social,
54 and practical domains (1). People with ID have a higher risk of contracting COVID-19, have
55 poorer health outcomes than the general public, and are on average six times more likely than the
56 general population to die from COVID-19 following hospital admission (2–5). COVID-19 was
57 the leading cause of death among those with intellectual and developmental disabilities in 2020
58 (6). People with specific diagnoses associated with ID are particularly prone to increased risk of
59 hospitalization and death, including those with Down syndrome, Autism, cerebral palsy, and
60 fragile X syndrome (7–11). There are numerous reasons why people with ID are particularly
61 vulnerable to experiencing severe COVID-19 illness and death (12). Specifically, people with ID
62 may have difficulty accessing care as readily as the general population (13,14). Some live in
63 congregate settings in which COVID-19 has spread more easily (15,16). People with ID are also
64 much more likely to have preexisting conditions that raise the likelihood of experiencing severe
65 outcomes following COVID-19 infection, such as hereditary and cardiac conditions, inborn
66 errors of metabolism, respiratory conditions, and obesity (12). Finally, people with ID may have
67 more challenges with risk mitigation measures, such as masking and distancing (17).

68 The increased risk of COVID-19 and its consequences make people with ID a
69 particularly important group for vaccination. However, global use of vaccines during the
70 COVID-19 pandemic has differed based on regional public health efforts, allocation of vaccines,
71 type of vaccine, and vaccine acceptance. In low-income nations, challenges in COVID-19 testing
72 and vaccine availability, distribution, and administration are barriers to controlling the spread of

73 the epidemic (18). Further, COVID-19 protocols for preventing, mitigating, and
74 treating/managing infection are largely based upon the general population without considering
75 their effects on persons with ID. These practices have resulted in pandemic-related disparities
76 among those with ID, including poorer physical and mental health (19). Overall, social
77 disparities may have an outsized effect on health outcomes, healthcare access, and basic social
78 determinants of health including food availability, safe housing, and school and work
79 accommodations.

80 Enhancing equity of persons with ID in the tracking of vaccine uptake and pandemic-
81 related health outcomes is paramount (20). This can be achieved through partnerships with the
82 disability community and disability organizations. Special Olympics is an international non-
83 profit organization that provides sports competition and promotes health, education and
84 leadership opportunities to over five million people with ID in 200 countries (21). Early in the
85 COVID-19 pandemic, Special Olympics recognized the potential increased risk for people with
86 ID and created resources to help participants stay healthy and maintain connections among the
87 Special Olympics community. Special Olympics compiled and disseminated accessible resources
88 to program participants and the larger community on topics such as healthy behaviors during
89 COVID-19 (e.g., handwashing, wearing a face mask), resources designed to help participants
90 maintain fitness levels at home, and other virtual activities to maintain social connections with
91 participants, coaches, and friends (22). Prevention activities and the promotion of COVID-19
92 vaccination were largely carried out at the local level across the world, including low- and high-
93 income countries. Among the general population, COVID-19 infection, use of prevention
94 strategies, and vaccination varied by country economic levels (23–25). Special Olympics’s

95 presence across countries with varying economic levels drove the need to better understand
96 global characteristics of the COVID-19 pandemic among adults with ID.

97 The objective of this study was to investigate global rates of COVID-19 vaccination and
98 reasons not to vaccinate among adults with intellectual disabilities relative to World Bank
99 country economic income levels.

100 **Methods**

101 The Special Olympics COVID-19 survey was conducted with an online sample of adults
102 with intellectual disabilities 18 years or older who participated in Special Olympics sport, health,
103 schools/education, or leadership programming in 138 countries. Local staff distributed the survey
104 to Special Olympics participants and families. The survey was developed via the Qualtrics
105 platform (Qualtrics, Provo, UT) and remained open for responses from January through February
106 2022. Questions were self-reported by adults with ID, though proxy responses from family
107 members/caregivers or staff/volunteers were also accepted. The voluntary survey included
108 questions regarding demographics, disability characteristics, COVID-19 vaccination, and reasons
109 for non-vaccination. COVID-19 vaccination was measured by asking participants if they
110 received a COVID-19 vaccine. Those who had not received a COVID-19 vaccination or planned
111 to receive it were asked what the reasons were for their decision.

112 Data across 138 countries were categorized by the World Bank economic income levels
113 of low-income country (LIC), lower-middle income country (LMIC), upper-middle income
114 country (UMIC), and high-income country (HIC) for primary analyses (26). Analyses were
115 conducted to examine COVID-19 vaccination by diagnosis. Descriptive statistics were calculated
116 as count and proportion of responses. For all proportions, 95% margins of error were calculated

117 (27). Logistic regression was performed to highlight the associations between demographic
118 variables and country economic income level with COVID-19 vaccination rates. We chose a
119 priori to include demographic variables in the regression model while considering other
120 interpersonal (e.g., living situation) and macro (e.g., country economic level) variables. Pearson
121 Chi-squared tests estimated differences in vaccine acceptance across low and lower-middle
122 income countries (LLMIC) compared to upper-middle and high-income countries (UMHIC).
123 Analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing;
124 Vienna, Austria). This investigation was reviewed by the Oregon State University Institutional
125 Review Board, which determined that it does not meet the definition of human subjects research
126 under the regulations set forth by the Department of Health and Human Services 45 CFR 46.

127

128 **Results**

129 In total, 3560 individuals from 138 countries (181 country and state-level Special
130 Olympics Programs) responded to the survey. Survey respondents represented 18 LICs (n=410),
131 35 LMICs (n=1182), 41 UMICs (n=837), and 44 HICs (n=1131). Survey respondents included
132 adults with ID (38.3%), family/caregiver responding on behalf of an adult with ID (39.1%), and
133 program staff/volunteers responding on behalf of an adult and ID (22.6%). The median age
134 across adults with ID was 25 years (Q1-Q3: 21-33 years) with 59.0% male. Most adults with ID
135 (82.9%) lived with family. Participant demographics stratified by World Bank country economic
136 levels are presented in Table 1.

137

138 **Table 1. Global Survey Respondent Characteristics by World Bank Economic Income**
 139 **Level (%), 95% Margin of Error)^a**
 140

	Low- Income (n=410)	Lower-Middle Income (n=1182)	Upper-Middle Income (n=837)	High- Income (n=1131)	Total (n=3560)
Median Age (years), (Q1-Q3)	23 (20-26)	24 (20-28)	26 (21-34)	30 (24-38)	25 (21-33)
Sex					
Male	57.8% (53.0-62.6%)	60.0% (57.2-62.8%)	62.0% (58.7-65.3%)	56.1% (53.3-59.0%)	59.0% (57.4-60.6%)
Female	42.0% (37.2-46.7%)	39.7% (36.9-42.5%)	37.5% (34.2-40.8%)	43.3% (40.4-46.2%)	40.6% (39.0-42.2%)
Living arrangement					
Live with family	86.3% (83.0-89.7%)	86.5% (84.5-88.4%)	87.1% (84.8-89.4%)	74.8% (72.3-77.3%)	82.9% (81.7-84.1%)
Live on own	5.1% (3.0-7.3%)	4.7% (3.5-5.9%)	5.4% (3.8-6.9%)	14.1% (12.0-16.1%)	7.9% (7.0-8.7%)
Live in group home	8.0% (5.4-10.7%)	4.1% (3.0-5.3%)	3.0% (1.8-4.1%)	7.0% (5.5-8.5%)	5.2% (4.5-6.0%)
Other	0.5% (0.0-1.2%)	4.7% (3.5-5.9%)	4.5% (3.1-6.0%)	4.2% (3.0-5.3%)	4.0% (3.4-4.7%)
Diagnoses					
Autism	28.8% (24.4-33.2%)	15.4% (13.3-17.5%)	15.4% (13.0-17.9%)	22.3% (19.9-24.7%)	19.1% (17.8-20.4%)
Down syndrome	42.7% (37.9-47.5%)	29.2% (26.6-31.8%)	30.5% (27.3-33.6%)	21.3% (18.9-23.7%)	28.5% (27.1-30.0%)
Fragile X	7.3% (4.8-9.8%)	3.9% (2.8-5.0%)	1.9% (1.0-2.8%)	5.3% (4.0-6.6%)	4.3% (3.6-4.9%)
Cerebral Palsy	10.7% (7.7-13.7%)	8.3% (6.7-9.9%)	3.7% (2.4-5.0%)	5.5% (4.2-6.8%)	6.6% (5.8-7.4%)
Other ID	13.2% (9.9-16.4%)	44.9% (42.1-47.8%)	49.2% (45.8-52.6%)	47.6% (44.7-50.5%)	43.1% (41.5-44.7%)

141 ^aRespondents from 181 Special Olympics programs across 138 countries

142

143 Globally, 76.2% (74.8-77.6%) of participants received a COVID-19 vaccination while

144 49.5% (47.9-51.2%) received a COVID-19 booster (Table 2). Other ID (81.0%, 54.2%), Autism

145 (76.1%, 46.6%) and Down syndrome (75.0%, 49.8%) were the diagnoses with higher levels of
146 vaccine and booster receipt, respectively. COVID-19 vaccination status varied by economic
147 levels with UMIC and HIC respondents having the highest rates (93.0% (91.2-94.7%) and 93.5%
148 (92.1-95.0%), respectively), while LIC respondents reported the lowest proportion of vaccination
149 (38.0% (33.3-42.7%)). This trend continued for COVID-19 booster vaccinations with UMIC and
150 HIC respondents having the highest proportion (67.0% (63.8-70.2%) and 75.2% (72.7-77.7%),
151 respectively) and LIC respondents with the lowest proportion (14.7% (11.3-18.1%)). Figure 1
152 displays the receipt of COVID-19 vaccinations and boosters by World Bank economic levels.

153

154 **Table 2. Receipt of COVID-19 Vaccine and Booster by Intellectual Disability and Country**

155 **Income Level (% , 95% MoE)**

	Received COVID-19 vaccine	Received COVID-19 booster
Diagnosis*		
Autism (n=681)	76.1 (72.9-79.3)	46.6 (42.9-50.4)
Down Syndrome (n=1016)	75.0 (72.3-77.6)	49.8 (46.7-52.9)
Fragile X (n=152)	68.2 (60.8-75.6)	34.4 (26.9-42.0)
Cerebral Palsy (n=235)	55.8 (49.4-62.2)	34.8 (28.6-40.9)
Other ID (n=1535)	81.0 (79.0-83.0)	54.2 (51.7-56.7)
Country Income Level*		
Low-Income (n=410)	38.0 (33.3-42.7)	14.7 (11.3-18.1)
Lower-Middle Income (n=1182)	61.2 (58.4-63.9)	24.7 (22.2-27.1)
Upper-Middle Income (n=837)	93.0 (91.2-94.7)	67.0 (63.8-70.2)
High-Income (n=1131)	93.5 (92.1-95.0)	75.2 (72.7-77.7)
Total (n=3560)	76.2 (74.8-77.6)	49.5 (47.9-51.2)

156 * p<0.05 by Pearson Chi-square test

157

158 **Fig 1. Receipt of COVID-19 Vaccine and Booster by Country Economic Income Level.**

159

160 Univariate models of vaccination identified age and economic level to be positively
 161 associated with vaccination while living with family and having fragile X syndrome or cerebral
 162 palsy were inversely associated with vaccination (Table 3). In the multivariate logistic regression
 163 model, age (OR=1.04 per year [1.03, 1.05]), country economic level (OR=3.12 [2.81, 3.48]), and
 164 living with family (OR=0.70 [0.53, 0.92]) remained associated with vaccination status.

165

166 **Table 3. Univariate and multivariate logistic regression models of COVID-19 vaccination**
 167 **among Special Olympics global survey respondents (n=3560).**

Variables	Unadjusted Odds Ratio [95% CI]	Adjusted Odds Ratio [95% CI]
Age (year)	1.08 [1.07, 1.09]***	1.04 [1.03, 1.05] ***
Sex (male)	1.15 [0.98, 1.34]	1.20 [1.00, 1.43]
Country economic income level	3.39 [3.07, 3.76] ***	3.12 [2.81, 3.48] ***
Live with family	0.53 [0.41, 0.66] ***	0.70 [0.53, 0.92] *
Athlete versus proxy as respondent	1.05 [0.90, 1.23]	0.97 [0.81, 1.16]
Diagnosis		
Autism	0.99 [0.82, 1.21]	1.32 [0.72, 2.55]
Down syndrome	0.91 [0.77, 1.07]	1.41 [0.76, 2.78]
Fragile X	0.66 [0.46, 0.94]*	0.76 [0.37, 1.66]
Cerebral palsy	0.36 [0.28, 0.48] ***	0.51 [0.26, 1.03]
Other	1.61[1.37, 1.89] ***	1.21 [0.65, 2.42]

168 Note: * P < 0.05, ** P < 0.01, *** P < 0.001.

169

170 Globally, among those not vaccinated for COVID-19, respondents in LLMICs reported a
 171 near threefold higher willingness to vaccinate (74.1% (70.9-77.3%)) compared to UMHICs
 172 (26.5% (19.0-34.0%)) ($\chi^2 = 111.4, p < 0.001$) (Table 4). The primary reasons to not vaccinate

173 differed among adults with ID in LLMICs and UMHICs ($p < 0.05$ by Pearson Chi-square test). In
174 LIC, the most common reason for not vaccinating was having no access to vaccination (41.2%
175 (29.5-52.9%)). Globally, the most common reasons for not vaccinating were concerns about side
176 effects (42.3%, (36.5-48.1%)) and parent/guardian not wanting the adult with ID to vaccinate
177 (31.5% (26.1-37.0%)).

Table 4. COVID-19 Vaccination Acceptance Among Unvaccinated Respondents and Reasons to Not Vaccinate (% , 95% Margin of Error).

	Low- Income	Lower-Middle Income	Upper-Middle Income	High-Income	Total
Plan to vaccinate	n=253	n=458	n=59	n=73	n=843
Yes	73.1% (67.7-78.6%)	74.7% (70.7-78.7%)	35.6% (23.4-47.8%)	19.2% (10.1-28.2%)	66.7% (63.5-69.8%)
No	7.9% (4.6-11.2%)	5.2% (3.2-7.3%)	30.5% (18.8-42.3%)	53.4% (42.0-64.9%)	12.0% (9.8-14.2%)
Not sure	19.0% (14.1-23.8%)	20.1% (16.4-23.8%)	33.9% (21.8-46.0%)	27.4% (17.2-37.6%)	21.4% (18.6-24.1%)
Reasons to not vaccinate	n=68	n=116	n= 38	n=57	n=279
Vaccine not safe*	16.2% (7.4-24.9%)	25.0% (17.1-32.9%)	34.2% (19.1-49.3%)	47.4% (34.4-60.3%)	28.7% (23.4-34.0%)
Concerned about side effects*	19.1% (9.8-28.5%)	40.5% (31.6-49.5%)	60.5% (45.0-76.1%)	61.4% (48.8-74.0%)	42.3% (36.5-48.1%)
Vaccine will not work*	7.4% (1.1-13.6%)	9.5% (4.2-14.8%)	34.2% (19.1-49.3%)	33.3% (21.1-45.6%)	17.2% (12.8-21.6%)
Distrust government*	7.4% (1.1-13.6%)	5.2% (1.1-9.2%)	18.4% (6.1-30.7%)	28.1% (16.4-39.7%)	12.2% (8.3-16.0%)
Distrust vaccine manufacture*	4.4% (0.0-9.3%)	0.9% (0.8-2.5%)	18.4% (6.1-30.7%)	28.1% (16.4-39.7%)	9.7% (6.2-13.1%)

Prior negative vaccine experience*	1.5% (0.0-4.3%)	6.0% (1.7-10.4%)	15.8% (4.2-27.4%)	19.3% (9.1-29.5%)	9.0% (5.6-12.3%)
Not enough information about the vaccine	7.4% (1.1-13.6%)	31.9% (23.4-40.4%)	18.4% (6.1-30.7%)	26.3% (14.9-37.7%)	22.9% (18.0-27.9%)
No access to vaccine*	41.2% (29.5-52.9%)	7.8% (2.9-12.6%)	2.6% (0.0-7.7%)	0.0% (0.0-0.0%)	13.6% (9.6-17.6%)
Religious objection*	1.5% (0.0-4.3%)	2.6% (0.0-5.5%)	2.6% (0.0-7.7%)	26.3% (14.9-37.7%)	7.2% (4.1-10.2%)
Do not have transportation	16.2% (7.4-24.9%)	0.9% (0.0-2.5%)	2.6% (0.0-7.7%)	0.0% (0.0-0.0%)	4.7% (2.2-7.1%)
Don't know where to get vaccinated	7.4% (1.1-13.6%)	0.0% (0.0-0.0%)	0.0% (0.0-0.0%)	0.0% (0.0-0.0%)	1.8% (0.2-3.3%)
Do not like needles	17.6% (8.6-26.7%)	31.0% (22.6-39.5%)	15.8% (4.2-27.4%)	17.5% (7.7-27.4%)	22.9% (18.0-27.9%)
Parent/ guardians do not want me to vaccinate	26.5% (16.0-37.0%)	32.8% (24.2-41.3%)	23.7% (10.2-37.2%)	40.4% (27.6-53.1%)	31.5% (26.1-37.0%)
Other	1.5% (0.0-4.3%)	6.0% (1.7-10.4%)	7.9% (0.0-16.5%)	12.3% (3.8-20.8%)	6.5% (3.6-9.3%)

* P < 0.05 by Pearson Chi-square test

Discussion

This study identified an association between country economic level and COVID-19 vaccination and reasons for not accepting vaccine among adults with ID. Participants from LLMICs reported fewer COVID-19 vaccinations than those from UMHICs and a higher willingness to vaccinate among those who are not yet vaccinated. The most common reasons for not vaccinating offer opportunities to address concerns about vaccine side effects and family caregivers' apprehension to vaccinate this high-risk population.

Over 75% of adults with ID in the current study were vaccinated against COVID-19 compared to 60% of the global population during the same time period (28). The relatively higher rates of COVID-19 vaccination among adults with ID in UMHICs suggest evidence of effective public health policies and favorable vaccine acceptance. At the time of this study, governments across the world implemented universal policies for vaccine delivery for vulnerable populations(29). The high rates of vaccination found in our study are compatible with favorable vaccine uptake among those with ID reported by Hatton et al. (83.5% vaccination rate) and Iadorala et al. (87.0% of the participants willing to get the COVID-19 vaccine) (30,31).

Despite overall high rates of vaccination among adults with ID, there were dramatic differences in vaccination across country economic levels. Lower overall vaccination in LICs compared to HICs is consistent with global COVID-19 vaccine dosages administered. As of January 2, 2022, *Our World in Data* reported higher levels of COVID-19 vaccine doses administered among UMICs (169.73 per 100 people) and HICs (166.18) compared to LMICs (84.12) and LICs (10.67)(32). Such findings suggest a lack of resources and infrastructure to vaccinate large populations among many LLMICs (33). As shown by the rates of under-

vaccinated children in LLMICs, vaccine infrastructure may be inadequate for large scale pandemic response (33).

Among those not vaccinated, more adults with ID from LLMICs planned to receive the COVID-19 vaccine compared to UMHICs. Among the unvaccinated population overall, LLMICs generally show higher willingness to accept vaccines than higher income countries (34–36). However, a recent study indicates growing pockets of vaccine hesitancy (37). As vaccines become more accessible to LLMIC, providers should focus communication on building trust, working with trusted stakeholders (e.g., community health workers), and engaging in broad community outreach to reduce vaccine hesitancy and rebuild confidence in vaccination programs for vulnerable and underserved communities (36).

Our findings document the most common reasons that adults with ID did not vaccinate across multiple levels of the sociological framework (38). Vaccination campaigns that target multiple levels of the socioecological model, focus on dialogue-based communication, and include community stakeholders yield better outcomes (37). At the individual level, concerns about vaccine side-effects and safety were top reasons for not receiving a COVID-19 vaccine across country economic levels. However, higher rates of respondents in UMHICs expressed concerns about side effects and safety than LLMICs. Those in UMHICs also expressed skepticism that the vaccine would work, which is consistent with prior research (39). At the interpersonal level of influence, the decision to vaccinate was significantly influenced by caregivers. Globally, parent/guardian restriction for vaccination was a primary reason those with ID were not vaccinating for COVID-19. These results complement Iadorola et al.'s (2022) study where those making decisions on behalf of a person with ID had more vaccine hesitancy than those with ID themselves (31). These collective findings highlight the need to provide vaccine

outreach and education tailored to caregivers' apprehension towards COVID-19 vaccination. Providing clear information about vaccine risks and incorporating trusted sources of information, including health care providers, may improve vaccine uptake worldwide for those with ID.

This study has several limitations. Findings are from a sample of adults with ID who participate in Special Olympics programming and may not be generalizable to the broader population of persons with ID. The study population includes 181 countries and states with Special Olympics affiliates but is not representative of all countries within economic levels. Because the survey was online, participants without internet access could not be included and likely contributed to underestimates of vaccination. As COVID-19 vaccination were self-reported, the vaccination type and dosage were not available for analysis. Nonetheless, this is the largest study of COVID-19 vaccination among people with ID to date that included representation from three-fourths of the world's countries.

Conclusion

This global study identified a significant association of country economic level on rates of COVID-19 vaccination and reasons for not accepting vaccine among adults with ID. Adults with ID from low and low-middle income countries reported fewer COVID-19 vaccinations, and indicated that the reason for not vaccinating was reduced access. Globally, COVID-19 vaccination levels among adults with ID were higher than the general population. Findings support the need to implement public health interventions that address family caregivers' apprehension to vaccinate this high-risk population.

Acknowledgments

The authors would like to thank the Special Olympics program staff around the world for their assistance in collecting this information.


References

1. Tassé M, Luckasson R, Schalock R. The Relation Between Intellectual Functioning and Adaptive Behavior in the Diagnosis of Intellectual Disability. *Intellectual and Developmental Disabilities*. 2016 Dec 1;54:381–90.
2. Nygren M, Lulinski A. State of the Science on COVID-19 and People with IDD [Research brief]. American Association on Intellectual and Developmental Disabilities. 2020;
3. Turk MA, Landes SD, Formica MK, Goss KD. Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. *Disability and Health Journal*. 2020 Jul 1;13(3):100942.
4. Henderson A, Fleming M, Cooper SA, Pell J, Melville C, MacKay D, et al. COVID-19 infection and outcomes in a population-based cohort of 17,173 adults with intellectual disabilities compared with the general population [Internet]. medRxiv; 2021 [cited 2022 May 27]. p. 2021.02.08.21250525. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.08.21250525v1>
5. Gleason, Jonathan, Ross, Wendy, Fossi, Alexander, Blonsky, Heather, TobiasJane, StephensMary. The Devastating Impact of Covid-19 on Individuals with Intellectual Disabilities in the United States. *NEJM Catalyst Innovations in Care Delivery* [Internet]. 2021 Mar 5 [cited 2022 Apr 6]; Available from: <https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0051>
6. Landes SD, Finan JM, Turk MA. COVID-19 mortality burden and comorbidity patterns among decedents with and without intellectual and developmental disability in the US. *Disability and Health Journal*. 2022 Sep;101376.
7. Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. *Ann Intern Med*. 2021 Apr 20;174(4):572–6.
8. Malle L, Gao C, Hur C, Truong HQ, Bouvier NM, Percha B, et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. *Genet Med*. 2021 Mar;23(3):576–80.
9. Altable M. Neuroinflammation links COVID-19 and fragile X syndrome: Role of MMP-9, IGF-1, IL-10, metformin, statins and curcumin. *Qeios* [Internet]. 2021 Feb 17 [cited 2022 May 24]; Available from: <https://www.qeios.com/read/KO4C77>
10. Krieger I, Erez G, Weinstein O, Cohen AD, Tzur Bitan D. COVID-19 Morbidity Among Individuals with Autistic Spectrum Disorder: A Matched Controlled Population-Based Study. *J Autism Dev Disord* [Internet]. 2021 Jul 8 [cited 2022 May 24]; Available from: <https://doi.org/10.1007/s10803-021-05187-2>

11. Brandenburg JE, Fogarty MJ, Sieck GC. Why individuals with cerebral palsy are at higher risk for respiratory complications from COVID-19. *Journal of Pediatric Rehabilitation Medicine*. 2020 Jan 1;13(3):317–27.
12. Courtenay K, Perera B. COVID-19 and people with intellectual disability: impacts of a pandemic. *Irish Journal of Psychological Medicine*. 2020 Sep;37(3):231–6.
13. Baumbusch J, Moody E, Hole R, Jokinen N, Stainton T. Using Healthcare Services: Perspectives of Community-Dwelling Aging Adults With Intellectual Disabilities and Family Members. *Journal of Policy and Practice in Intellectual Disabilities*. 2019;16(1):4–12.
14. Doherty AJ, Atherton H, Boland P, Hastings R, Hives L, Hood K, et al. Barriers and facilitators to primary health care for people with intellectual disabilities and/or autism: an integrative review. *BJGP Open* [Internet]. 2020 Aug 1 [cited 2022 Apr 4];4(3). Available from: <https://bjgpopen.org/content/4/3/bjgpopen20X101030>
15. Landes SD, Turk MA, Formica MK, McDonald KE, Stevens JD. COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State. *Disability and Health Journal*. 2020 Oct 1;13(4):100969.
16. Landes SD, Turk MA, Wong AWWA. COVID-19 outcomes among people with intellectual and developmental disability in California: The importance of type of residence and skilled nursing care needs. *Disability and Health Journal*. 2021 Apr 1;14(2):101051.
17. Doody O, Keenan PM. The reported effects of the COVID-19 pandemic on people with intellectual disability and their carers: a scoping review. *Annals of Medicine*. 2021 Jan 1;53(1):786–804.
18. Sheikh AB, Pal S, Javed N, Shekhar R. COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation. *Infectious Disease Reports*. 2021 Jun;13(2):429–36.
19. Taggart L, Mulhall P, Kelly R, Trip H, Sullivan B, Wallén EF. Preventing, mitigating, and managing future pandemics for people with an intellectual and developmental disability - Learnings from COVID-19: A scoping review. *Journal of Policy and Practice in Intellectual Disabilities*. 2022;19(1):4–34.
20. Andrews EE, Ayers KB, Brown KS, Dunn DS, Pilarski CR. No body is expendable: Medical rationing and disability justice during the COVID-19 pandemic. *American Psychologist*. 2021;76(3):451–61.
21. Reach Report [Internet]. Resources. [cited 2022 Jun 24]. Available from: <https://resources.specialolympics.org/governance/reach-report>
22. Temple VA. COVID-19 Pandemic and Individuals With Intellectual Disability: Special Olympics as an Example of Organizational Responses and Challenges. *Adapted Physical Activity Quarterly*. 2022 Jan 20;1(aop):1–18.

23. Valero M, Valero-Gil JN. Determinants of the number of deaths from COVID-19: differences between low-income and high-income countries in the initial stages of the pandemic. *International Journal of Social Economics*. 2021 Jan 1;48(9):1229–44.
24. Duan Y, Shi J, Wang Z, Zhou S, Jin Y, Zheng ZJ. Disparities in COVID-19 Vaccination among Low-, Middle-, and High-Income Countries: The Mediating Role of Vaccination Policy. *Vaccines*. 2021 Aug;9(8):905.
25. Walker P, Whittaker C, Watson O, Baguelin M, Ainslie K, Bhatia S, et al. Report 12: The global impact of COVID-19 and strategies for mitigation and suppression [Internet]. 19. 2020 Mar [cited 2022 Jun 13]. Available from: <http://spiral.imperial.ac.uk/handle/10044/1/77735>
26. World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2022 May 25]. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>
27. Isserlis L. On the Value of a Mean as Calculated from a Sample. *Journal of the Royal Statistical Society*. 1918 Jan;81(1):75.
28. COVID-19 Data Explorer [Internet]. Our World in Data. [cited 2022 Aug 8]. Available from: <https://ourworldindata.org/coronavirus-data-explorer>
29. COVID-19 vaccination policy [Internet]. Our World in Data. [cited 2022 Aug 5]. Available from: <https://ourworldindata.org/grapher/covid-vaccination-policy>
30. Hatton C, Bailey T, Bradshaw J, Caton S, Flynn S, Gillooly A, et al. The willingness of UK adults with intellectual disabilities to take COVID-19 vaccines. *Journal of Intellectual Disability Research*. 2021;65(11):949–61.
31. Iadarola S, Siegel JF, Gao Q, McGrath K, Bonuck KA. COVID-19 vaccine perceptions in New York State’s intellectual and developmental disabilities community. *Disability and Health Journal*. 2022 Jan 1;15(1):101178.
32. Total COVID-19 vaccine doses administered per 100 people [Internet]. Our World in Data. [cited 2022 Aug 5]. Available from: <https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita>
33. Figueroa JP, Bottazzi ME, Hotez P, Batista C, Ergonul O, Gilbert S, et al. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. *The Lancet*. 2021 Feb 13;397(10274):562–4.
34. Patwary MM, Alam MA, Bardhan M, Disha AS, Haque MZ, Billah SM, et al. COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis. *Vaccines*. 2022 Mar;10(3):427.

35. Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. *Nat Med*. 2021 Aug;27(8):1385–94.
36. Bhopal S, Nielsen M. Vaccine hesitancy in low- and middle-income countries: potential implications for the COVID-19 response. *Arch Dis Child*. 2021 Feb;106(2):113–4.
37. Simas C, Larson HJ. Overcoming vaccine hesitancy in low-income and middle-income regions. *Nat Rev Dis Primers*. 2021 Jun 10;7(1):1–2.
38. Latkin C, Dayton LA, Yi G, Konstantopoulos A, Park J, Maulsby C, et al. COVID-19 vaccine intentions in the United States, a social-ecological framework. *Vaccine*. 2021 Apr 15;39(16):2288–94.
39. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. *Vaccines*. 2021 Feb;9(2):160.



Figure